
DIGITAL JOURNEY TRACKING

# Plaque Psoriasis Digital Landscape







# Contents

**METHODOLOGY & SAMPLE** 

INSIGHTS

**DETAILED FINDINGS** 


The Digital Journey Tracker provides a foundation for *digital*strategy & media planning decisions based on target

customers' real-time browsing behavior and the

competitive digital landscape

### How It Works

A custom web extension passively captures target customer's healthcare browsing activity in real time



# **Channels Captured**




# Paid Search

**Banner Ads** 



# Case Study Sample





Browsing behavior was captured for thirteen pre-LOE treatments in the study, including biologics, topicals, and oral systemics

TREATMENT CATEGORY

Biologics

BRAND NAME
Bimzelx, Cosentyx, Taltz, Siliq

MECHANISM OF ACTION
MECHANISM OF ACTION
Other

BRAND NAME
BRAND NAME
Skyrizi, Tremfya, Ilumya

MECHANISM OF ACTION
MECHANISM OF ACTION
Other


Stelara, Enbrel

TREATMENT
CATEGORY

Topicals

BRAND NAME
Zoryve, Vtama





# **Contents**

**METHODOLOGY & SAMPLE** 

**INSIGHTS** 

**DETAILED FINDINGS** 

**Biologics** capture the most HCP attention, but **no single brand stands out in this category** despite strong digital marketing efforts from Bimzelx, Cosentyx, Skyrizi, and Tremfya



**Zoryve** draws more than **twice** as much HCP attention as **Vtama** and leads the Topical category across banner ads, paid search, and email campaigns




**Otezla** commands the **lion's share of attention** within the **Oral Systemic category,** outperforming Sotyktu in both banner and paid search advertising



**Brand websites** are HCPs' **go-to source for PsO treatment information**, accounting for over half of HCPs' Tx-related browsing time

### **Share of Digital Attention**






**Biologics** 

■ Other Biologics^


Topicals


oral Systemics

### **Share of Exposures**









# **Contents**

**METHODOLOGY & SAMPLE** 

INSIGHTS

**DETAILED FINDINGS** 

# Biologics see intense competition for HCP attention, while Zoryve and Otezla lead within their respective treatment categories




PsO Tx-Related Content Browsing
Jan'25 - Jun'25

### Digital Share of Attention\* ■ Sotyktu Otezla Vtama Zoryve 59% ■Other Biologics^ 5% Taltz Cosentyx 28% Stelara Enbrel 13% 10% ■Tremfya 12% Skyrizi **Biologics Topicals Oral Systemics**

### % of Time Spent Browsing Treatment Content

### Sources of Attention (by Treatment type)\*




% of Time Spent Browsing Treatment Content by Site Type

■ Bimzelx


# Cosentyx accounts for nearly one-quarter of banner ad exposures, roughly twice the share of any of the next five leading brands individually




Exposures to Display Ads
Jan'25 - Jun'25







### Sample Display Ads





### PsO brands advertise across a wide range of endemic sites



Exposures to Display Ads Jan'25 - Jun'25

**Share of Exposures by Host Site** (only the top 10 websites are shown)

			Biologics						Oral Systemics		Topicals	
		Overall	Cosentyx	Bimzelx	Skyrizi	Tremfya	Taltz	Ilumya	Otezla	Sotyktu	Zoryve	Vtama
Endemic	webmd.com											
	psoriasis.org											
	medscape.com											
	dermnetnz.org											
	inspire.com											
Websites	Medpagetoday		Available As Part									
	drugs.com		of Full Report									
	health line.com											
	aad.org											
	my.clevelandclinic											
	Other Endemic websites											
	Non-Endemic Websites											
Share	of all Exposures	100%	24%	16%	13%	11%	5%	2%	12%	3%	10%	4%

# HCPs typically search specific Tx's in 60% of their PsO-related searches; Skyrizi, Zoryve, and Otezla lead their categories in sponsored ad exposures




Paid Search Ad Exposures Jan'25 - Jun'25


### **Brand Share of Paid Search Exposures\***



60%

Of PsO-Related Searches Were for Specific Brands/Molecules





### Zoryve, Tremfya, and Cosentyx collectively account for over 60% of **PsO** treatment-related emails reaching HCP inboxes

■ Sotyktu

Otezla

Vtama

Zoryve

Taltz

Bimzelx

Cosentyx

■ Tremfya

■ Other Biologics^



**Emails Received** Jan'25 - Jun'25


### **Share of Emails\***

# 51% 5% 31% 17% **Biologics** Topicals **Oral Systemics**

% of Indication-Related Emails

### **Sample Emails**







# Get in touch

robert.faria@zoomrx.com